Dako PD-L1检测试剂盒（免疫组织化学法）(PD-L1 IHC 22C3 pharmDx) 判读培训教程
PD-L1 是经证实，可以用于预测 NSCLC 患者是否能从 KEYTRUDA®（帕博利珠单抗）治疗获益的生物标记物，本课程将引领您一起，了解如何对以 PD-L1 IHC 22C3 pharmDx 进行 PD-L1 检测的结果进行判读与评分，以及肿瘤比例评分 (TPS)。
Dako PD-L1 IHC 22C3 pharmDx
判读培训教程通过问答互动与提供实验病例供实践的方式，帮助您准确地：
- 了解 PD-L1 病理学的核心原则
- 了解染色样本 PD-L1 表达的评估步骤
- 识别影响 PD-L1 判读的常见影响因素
- 提供多个患者的 PD-L1 数字病理图片的实例, 供学员实习评分技巧
了解 PD-L1 IHC 22C3 pharmDx
预期用途
开始
立即注册
已经注册？
立即登录
参考文献
- Keytruda [prescribing information].Kenilworth, NJ: Merck & Co.; 2019
- PD-L1 IHC 22C3 pharmDx [包装说明书]，Carpinteria, CA: Dako，安捷伦病理学解决方案；2019
- Reck M, Rodríguez-Abreu D, Robinson AG, et al.Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer.N Engl J Med.2016; Oct 9 [Epub ahead of print]. doi: 10.1056/NEJMoa1606774
- Herbst RS, Baas P, Kim DW, et al.Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.Lancet.2016;387(10027):1540-1550
- Roach C, Zhang N, Corigliano E, et al.Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-small-cell lung cancer.Appl Immunohistochem Mol Morphol.2016;24:392-397
- Dolled-Filhart M, Roach C, Toland G, et al.Development of a companion diagnostic for pembrolizumab in non-small cell lung cancer using immunohistochemistry for programmed death ligand-1.Arch Pathol Lab Med.2016. doi:10.5858/arpa.2015-0542-OA
- Herbst RS, Soria JC, Kowanetz M, et al.Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Nature.2014; 515(7528):563-567 - Tumeh PC, Harview CL, Yearley JH, et al.PD-1 blockade induces responses by inhibiting adaptive immune resistance.Nature.2014;515(7528):568-571
- Hanahan D, Weinberg RA.Hallmarks of cancer: the next generation.Cell.2011;144(5):646-674
- Sharpe AH, Freeman GJ.The B7-CD28 superfamily.Nat Rev Immunol.2002;2(2):116-126
- Keir ME, Butte MJ, Freeman GJ, Sharpe AH.PD-1 and its ligands in tolerance and immunity.Annu Rev Immunol.2008;26:677-704
- Freeman GJ, Long AJ, Iwai Y, et al.Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.J Exp Med.2000;192(7):1027-1034
- Dong H, Strome SE, Salomao DR, et al.Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.Nat Med.2002;8(8):793-800
- Mu CY, Huang JA, Chen Y, Chen C, Zhang XG.High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation.Med Oncol.2011;28(3):682-688
- Gettinger S, Herbst RS.B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction.Cancer J.2014;20(4):281-289
- Brahmer JR, Tykodi SS, Chow LQ, et al.Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.N Engl J Med.2012;366(26):2455-2465
- Topalian SL, Hodi FS, Brahmer JR, et al.Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.N Engl J Med.2012;366(26):2443-2454
- Boland JM, Kwon ED, Harrington SM, et al.Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung.Clin Lung Cancer.2013;14(2):157-163
- Chen YB, Mu CY, Huang JA.Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study.Tumori.2012;98(6):751-755
- Velcheti V, Schalper KA, Carvajal DE, et al.Programmed death ligand-1 expression in non-small cell lung cancer.Lab Invest.2014;94(1):107-116
- Garon EB, Rizvi NA, Hui R, et al.Pembrolizumab for the treatment of non-small cell lung cancer.N Engl J Med.2015;372(21):2018-2028